Charting a new path for AI-native therapeutics
Ailux is building an AI-native infrastructure to bring transformative medicines to patients, advanced AI, a comprehensive wet lab, and global clinical capabilities, vertically integrated to move novel candidates from idea to clinic.
These technologies enable greater precision, from de novo design and multiparametric optimization to complex multispecific architectures. Together, these capabilities support our mission to develop best-in-class therapies for diseases where current treatments fall short.
Programmable AI Biologists
AI agents amplify human expertise, efficiency and creativity in drug development.
Grounded in real-world science
Built on deep scientific know-how and insights gained from real-world therapeutic development.
End-to-end workflows
Supporting every stage from target identification to drug optimization and translational science.
Continuously learning
Communicating and adapting to help drive faster decisions and higher-quality outcomes.
State-of-the-Art AI Models
AI models prove their worth at the bench, not on paper.
Trained on proprietary data
Built on our proprietary, curated datasets — accuracy that holds up in the lab, not just on paper.
An integrated model suite
XtalFold® for structure prediction, XenProt® for generative design, and Xentient® for affinity and developability.
Validated and iterated
Rigorous wet-lab validation and rapid iteration drive differentiated candidates with better efficacy and safety.
The #1 AI-Grade Biologics Dataset
Data is the fuel and the bottleneck of AI-native therapeutic development.
Generated at scale
An integrated high-throughput system produces superior biologics datasets at scale, in-house.
Tens of billions of data points
AtlaX™ captures molecular and therapeutic features far beyond what is publicly available.
A durable advantage
Depth and diversity strengthen model performance — helping us create better therapies for patients.
Comprehensive Wet Lab
A 30,000+ sq. ft. wet lab, built in parallel with our AI from day one.
Rapid in-house evaluation
AI-generated designs are tested through high-throughput, large-scale specialized assays.
A closed feedback loop
Experimentation and computation feed each other continuously, sharpening every iteration.
Preclinical to global trials
A seamless transition from preclinical development into global trials and beyond.
Validating the AI frontier together
We believe the future of medicine will be shaped through the convergence of AI, biology, and strategic collaboration. By working alongside leading pharmaceutical innovators, we are helping redefine how biologic therapies are discovered, designed, and ultimately delivered to patients.
Eli Lilly selected Ailux’s AI-powered bispecific antibody platform to accelerate the development of next-generation biologic therapies. The collaboration highlights the strength of our integrated approach to therapeutic design and the potential of AI to unlock novel treatment opportunities for patients.
Ailux licensed its proprietary XtalFold® platform to Janssen, providing rapid, AI-driven structural insights to accelerate biologics development. This collaboration underscores the potential of our technology to support innovation across multiple stages of therapeutic development.
UCB licensed XtalFold®, Ailux’s proprietary AI platform to advance the development of differentiated therapeutic candidates. The collaboration highlights the increasing role of AI in biologics innovation and reinforces the value of our platform in helping industry leaders translate scientific insights into meaningful therapies.
